Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
K-NADIR: Fulzerasib + Sintilimab + Chemo as Neoadjuvant Therapy in KRAS G12C NSCLC
NCT07492342Phase 2Recruiting
- Start
- Jan 2026
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fulzerasib in non-small cell lung cancer (NSCLC). Started Jan 2026; status: recruiting.
02
Drugs
fulzerasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07492342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07492342.